Brett Hagen
Equibles does not estimate personal net worth.
Get an email with a short summary when Kalaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get KLRS alertsAbout Brett Hagen
Brett Hagen is recorded as CFO at Kalaris Therapeutics, Inc. (KLRS) since March 18, 2025. Kalaris Therapeutics, Inc. reported in an 8-K filed July 20, 2026 that Brett Hagen resigned as Senior Vice President, Finance and Chief Accounting Officer, effective July 27, 2026. Kalaris Therapeutics, Inc. reported in an 8-K filed April 10, 2026 that Brett Hagen was appointed principal financial officer, effective April 14, 2026. The proxy statement of Kalaris Therapeutics, Inc. reports total compensation of $1,439,174 for Brett Hagen in fiscal 2025, including a base salary of $397,301. Disclosed compensation is on record for 2 fiscal years. Kalaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kalaris Therapeutics, Inc. includes Andrew Oxtoby (CEO and Board Member), Diana M. Brainard (CEO and Board Member), Vikas Sinha (CEO) and 7 others.
“On July 14, 2026, Brett Hagen notified the Company of his decision to resign as the Company’s Senior Vice President, Finance and Chief Accounting Officer, effective as of July 27, 2026.”
“As a result of Mr. Gall's resignation, Brett Hagen, the Company's Chief Accounting Officer and principal accounting officer, will also serve as the Company's principal financial officer, effective as of the Separation Date.”
Affiliation history
-
Current
2026-04-14–present
-
Current
2025-03-18–present
-
Start not stated–2026-07-27
Company network
Leadership on record at Kalaris Therapeutics, Inc.
- Andrew Oxtoby CEO, Board Member
- Diana M. Brainard CEO, Board Member
- Vikas Sinha CEO
- David Hallal Chairman, Board Member
- Liisa Bayko CFO
- Matthew Gall CFO
- Amy Vandekop Chief Accounting Officer
- Anthony Adamis Board Member
- Derek Adams, Ph.D. Board Member
- Laurie Keating Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Kalaris Therapeutics, Inc. (KLRS) | Chief Accounting Officer and AlloVir’s former Chief Accounting Officer | $397,301 | $1,439,174 |
| 2024 | Kalaris Therapeutics, Inc. (KLRS) | AlloVir’s Former Chief Accounting Officer and our Current Chief Accounting Officer | $385,320 | $796,311 |